Press Release: Novartis provides an update on -2-

Inadequately Controlled with H1-antihistamines [online] April 2020.

Available from: https://clinicaltrials.gov/ct2/show/NCT03580369 [Last

accessed: December 2021].

13. ClinicalTrials.gov. NCT03580356. A Phase III Study of the Efficacy and

Safety of Ligelizumab in the Treatment of CSU in Adolescents and Adults

Inadequately Controlled with H1-antihistamines [online] March 2020.

Available from: https://clinicaltrials.gov/ct2/show/NCT03580356 [Last

accessed: December 2021].

14. Severin T, Maurer M, Giménez-Arnau A, et al. Ligelizumab versus

omalizumab in CSU: Phase 3 design and rationale. Presented at the 4th

GA(2)LEN Global Urticaria Forum; December 5--6 2018; Berlin, Germany.

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Michael Meo Louise Clark

Novartis Global Media Relations Novartis Global Communications

+1 862 274 5414 (mobile) +41 79 123 8172 (mobile)

michael.meo@novartis.com louise.clark@novartis.com

Julie Masow

Novartis US External Communications

+1 862 579 8456

julie.masow@novartis.com

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Samir Shah +41 61 324 7944 Sloan Simpson +1 862 345 4440

Thomas Hungerbuehler +41 61 324 8425 Alina Levchuk +1 862 778 3372

Isabella Zinck +41 61 324 7188 Parag Mahanti +1 973-876-4912

(END) Dow Jones Newswires

December 20, 2021 01:15 ET (06:15 GMT)